Poly-MVA® and prostate health: Shari Lieberman PhD, CNS, FACN discusses cancer case studies with the Foundation for Advancement in Cancer Research

Townsend Letter for Doctors and Patients, August-Sept, 2006

FACR: In what way can Poly-MVA support prostate health?

Dr. Lieberman: A number of studies show how Poly-MVA can support the health of individuals with mutagenic concerns, including prostate cancer. Dr. Forsythe presented further case studies, and Dr. Frank Antonawich presented his exciting and thorough work on the mechanism of action of Poly-MVA at the 13th Annual World Congress on Anti-Aging Medicine in December 2005. Dr. Forsythe's study followed hundreds of patients with Stage IV cancer with multiple origins--including prostate, breast, sarcoma, colon, lung, brain, bladder, and stomach--for three to 24 months.

In Forsythe's study, 14 of the 66 patients (21%) experienced a complete response rate of clinical remission. In 39 of the subjects (56%), there was a partial response rate. (A partial response rate was defined as a 50% reduction in tumor mass). In 15 of the patients (23%), the disease continued to progress. All subjects received conventional therapy together with Poly-MVA.

FACR: What an interesting outcome. Have there been other studies that focused on Poly-MVA and prostate cancer specifically?

Dr. Lieberman: I recently published the results of three case studies with Dr. Forsythe (Lieberman S, Forsythe JW. Poly-MVA for treating prostate cancer: a report on three cases. Alternative & Complementary Therapies. August 2005; 203-207). One case report profiled 73-year-old R.Z., whose PSA was 7.8 when diagnosed with stage 4 adenocarcinoma of the prostate in January 2001. His cancer had metastasized to his ribs and probably his liver. He also was diagnosed with a dilated left ureter with tumor nodules. Because of his partially obstructed ureter, he had difficulty urinating and rose four to five times nightly to urinate. R.Z. adamantly refused any conventional treatment.

From February 2001 to May 2004, R.Z. was placed on a supplement regimen of multivitamins and herbs. His PSA, however, continued to both lower and rise erratically until it reached a high of 11 in May 2004. At this time, he began taking Poly-MVA, two teaspoons, four times a day (q.i.d.), for six months, then decreased the dose to two teaspoons three times a day (t.i.d.). His PSA levels declined progressively, reaching 8.7 in February 2005. This was the first time he experienced a consistent decrease in his PSA levels. His stage IV prostate cancer has been stabilized for 11 months while on the Poly-MVA. He remains physically, mentally, and sexually active. He is now waking two to three times each night to urinate and no longer experiences obstructed urine flow. His performance scale results have been 100% perfect.

FACR: What were the results of the other case reports documented in the report you wrote with Dr. Forsythe?

Dr. Lieberman: One of the case reports focused on 59-year-old J.C., who was diagnosed with adenocarcinoma of the prostate in September 2004. The lesion on his prostate measured 10 mm x 5 mm--large enough to be palpable. His lymphocytes were low at 3.9 (normal range 24 to 44). He suffered from dysuria (painful or difficult urination) and hematuria (blood in the urine). J.C. adamantly refused conventional treatment, including chemotherapy and radiation or surgery. He was started on Poly-MVA, beginning on November 11, 2004. In combination with the IV treatment, he also consumed 20 mL (two teaspoons, twice a day [b.i.d.]) for the first week; 10 ml every day for the second week; and 40 mL (two teaspoons q.i.d.) the third week. He now remains on the oral dose he consumed the third week.